IN2015DN03928A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03928A
IN2015DN03928A IN3928DEN2015A IN2015DN03928A IN 2015DN03928 A IN2015DN03928 A IN 2015DN03928A IN 3928DEN2015 A IN3928DEN2015 A IN 3928DEN2015A IN 2015DN03928 A IN2015DN03928 A IN 2015DN03928A
Authority
IN
India
Prior art keywords
compound
formula
mek
inhibitor
disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
C Gregory Sowell
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IN2015DN03928A publication Critical patent/IN2015DN03928A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
IN3928DEN2015 2012-10-12 2013-10-14 IN2015DN03928A (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2015DN03928A true IN2015DN03928A (en:Method) 2015-10-02

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3928DEN2015 IN2015DN03928A (en:Method) 2012-10-12 2013-10-14

Country Status (31)

Country Link
US (4) US9771347B2 (en:Method)
EP (1) EP2909188B1 (en:Method)
JP (2) JP6300042B2 (en:Method)
KR (1) KR102204520B1 (en:Method)
CN (2) CN104837826B (en:Method)
AU (1) AU2013328929B2 (en:Method)
BR (1) BR112015008113B1 (en:Method)
CA (1) CA2889466C (en:Method)
CL (1) CL2015000926A1 (en:Method)
CR (2) CR20200237A (en:Method)
EA (1) EA030613B1 (en:Method)
ES (1) ES2671502T3 (en:Method)
GE (1) GEP201706690B (en:Method)
HK (1) HK1213567A1 (en:Method)
HR (1) HRP20180670T1 (en:Method)
IL (1) IL238116B (en:Method)
IN (1) IN2015DN03928A (en:Method)
MA (1) MA38085B1 (en:Method)
MX (2) MX372708B (en:Method)
MY (1) MY186549A (en:Method)
NZ (1) NZ706723A (en:Method)
PE (3) PE20191818A1 (en:Method)
PH (1) PH12015500785A1 (en:Method)
PL (1) PL2909188T3 (en:Method)
SA (1) SA515360271B1 (en:Method)
SG (1) SG11201502795VA (en:Method)
SI (1) SI2909188T1 (en:Method)
TR (1) TR201807861T4 (en:Method)
UA (1) UA115455C2 (en:Method)
WO (1) WO2014059422A1 (en:Method)
ZA (1) ZA201502349B (en:Method)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2969014T3 (es) 2015-06-30 2024-05-16 Genentech Inc Comprimidos de liberación inmediata que contienen un fármaco y procesos para la formación de los comprimidos
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
WO2018031865A1 (en) 2016-08-12 2018-02-15 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
BR112019005815A2 (pt) 2016-09-29 2019-06-25 Genentech Inc métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
EP4304592A1 (en) 2021-03-09 2024-01-17 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
WO2022216719A1 (en) 2021-04-06 2022-10-13 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
CN1094487C (zh) 1994-04-01 2002-11-20 盐野义制药株式会社 肟衍生物和含有其作为活性成分的杀菌剂
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU5610398A (en) 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
CA2290509A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
EP0993439B1 (en) 1997-07-01 2004-09-29 Warner-Lambert Company LLC 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
AU2180500A (en) 1998-12-15 2000-07-03 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
WO2000035436A2 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
YU45401A (sh) 1998-12-22 2004-07-15 Warner-Lambert Company Antikancerogena kombinacija
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
AU2483000A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Treatment of asthma with mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
NZ513432A (en) 1999-01-13 2004-02-27 Warner Lambert Co 1-heterocycle substituted diarylamines
WO2000041505A2 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Anthranilic acid derivatives
CN1177830C (zh) 1999-01-13 2004-12-01 沃尼尔·朗伯公司 苯并杂环和它们作为mek抑制剂的用途
BR9916885A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek
AU5912500A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
AU5785900A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
IL147619A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
AU2001247372A1 (en) 2000-03-15 2001-09-24 Warner Lambert Company 5-amide substituted diarylamines as mex inhibitors
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
NZ524120A (en) 2000-07-19 2005-08-26 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
AP2001002249A0 (en) * 2000-08-25 2001-09-30 Warner Lambert Co Process for making N-ARYL-ANTHRANILIC acids and their derivatives.
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
JP2005507411A (ja) 2001-10-31 2005-03-17 ファイザー・プロダクツ・インク 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
WO2003062191A1 (en) 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
AR038971A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AR038972A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
EP1515727A4 (en) 2002-06-11 2009-04-08 Merck & Co Inc INHIBITORS OF P38 KINASE (HALO-BENZO CARBONYL) HETEROBICYCLIC
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
WO2004078116A2 (en) 2003-03-03 2004-09-16 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
AU2004249495A1 (en) 2003-06-20 2004-12-29 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
EP1674452A4 (en) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
ES2389628T3 (es) 2003-11-19 2012-10-29 Array Biopharma, Inc. Inhibidores bicíclicos de MEK
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005058887A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivates
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
ZA200703912B (en) 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CA3052368A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2101759B1 (en) * 2006-12-14 2018-10-10 Exelixis, Inc. Methods of using mek inhibitors
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
AU2014381760B2 (en) 2014-02-07 2018-08-02 Sumitomo Chemical Company, Limited Method for producing (R)-1,1,3-trimethyl-4-aminoindane
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
PL2909188T3 (pl) 2018-08-31
PE20191818A1 (es) 2019-12-27
JP6300042B2 (ja) 2018-03-28
CL2015000926A1 (es) 2015-08-28
PH12015500785B1 (en) 2015-06-15
MY186549A (en) 2021-07-26
WO2014059422A1 (en) 2014-04-17
CN108948043A (zh) 2018-12-07
EA030613B1 (ru) 2018-08-31
US10239858B2 (en) 2019-03-26
ES2671502T3 (es) 2018-06-06
MX2020005533A (es) 2020-10-12
US20200392104A1 (en) 2020-12-17
CN104837826B (zh) 2018-07-27
AU2013328929B2 (en) 2018-01-04
EA201590700A1 (ru) 2015-09-30
KR20150067339A (ko) 2015-06-17
NZ706723A (en) 2018-07-27
PE20151494A1 (es) 2015-11-06
JP2015533175A (ja) 2015-11-19
MA38085A1 (fr) 2018-08-31
BR112015008113B1 (pt) 2022-05-24
GEP201706690B (en) 2017-06-26
CA2889466A1 (en) 2014-04-17
EP2909188B1 (en) 2018-03-07
TR201807861T4 (tr) 2018-06-21
PH12015500785A1 (en) 2015-06-15
HRP20180670T1 (hr) 2018-07-13
SI2909188T1 (en) 2018-07-31
CR20150245A (es) 2015-11-19
MX372708B (es) 2020-05-29
KR102204520B1 (ko) 2021-01-20
JP2018052973A (ja) 2018-04-05
US20170349569A1 (en) 2017-12-07
CN108948043B (zh) 2021-05-04
US10793541B2 (en) 2020-10-06
EP2909188A1 (en) 2015-08-26
CN104837826A (zh) 2015-08-12
PE20200387A1 (es) 2020-02-24
SG11201502795VA (en) 2015-05-28
IL238116B (en) 2018-06-28
ZA201502349B (en) 2019-12-18
HK1213878A1 (en) 2016-07-15
US20150210668A1 (en) 2015-07-30
SA515360271B1 (ar) 2016-05-19
BR112015008113A2 (pt) 2017-07-04
US9771347B2 (en) 2017-09-26
AU2013328929A1 (en) 2015-04-30
CA2889466C (en) 2021-09-14
MX2015004660A (es) 2015-08-07
UA115455C2 (uk) 2017-11-10
HK1213567A1 (zh) 2016-07-08
US11414396B2 (en) 2022-08-16
CR20200237A (es) 2020-07-26
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
IN2015DN03928A (en:Method)
NZ705705A (en) Ret inhibitor
PH12015502284A1 (en) Protein kinase inhibitors
PH12016500225A1 (en) Novel quinoline-substituted compound
MA40076A (fr) Inhibiteurs de syk
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
IN2015DN02929A (en:Method)
UA116239C2 (uk) Нові похідні піридину
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
PH12017500747A1 (en) Heterocyclic compound
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
IN2014DN10658A (en:Method)
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
IN2014KN01772A (en:Method)
GEP20176633B (en) Use of pidotimod to treat psoriasis
MY177247A (en) Method of production of human insulin methyl ester
IN2013MU02595A (en:Method)
GEP201706683B (en) Usage of pidotimod to treat inflammatory bowel diseases
UA58841U (ru) Способ профилактики и оздоровления поросят